Things are heating up quickly this summer for life science investors. Here’s who’s coming in droves with cash this week.
Closing its fourth fund for life sciences, venBio has rounded up $ 550 million invest in pharmaceutical companies developing therapies for unmet medical needs. Since its inception in 2011, the venture capital firm has raised nearly $ 1.5 billion in capital commitments and led investment rounds in 34 companies. “We remain committed to our unique approach and strategy and hope the results speak for themselves: our portfolio companies have brought four drugs to market for six clinical indications, and seven other drug candidates demonstrate promising efficacy. at an advanced stage, ”said partner Robert Adelman.
With $ 160 million in new Series B funds, Monogram Health is expanding its management of renal failure benefits to patients with renal failure in the United States. The platform helps patients manage their chronic kidney disease (CRF) and end-stage kidney disease at home. In partnership with health plans, this data-driven specialist home care approach improves patient outcomes and dramatically reduces costs to the healthcare system. More than 10% of the adult American population suffers from CRF, and many cases go untreated until the final stage of the disease. Currentlt, Monogram operates services in 20 states with a growing network of specialists.
A pioneer in the field of targeted protein stabilization, Stalix came out of stealth mode with a $ 63 million Series A. The opposite approach to the popular protein degradation track, protein stabilization strengthens the body’s mechanisms. A large number of diseases are the result of insufficient levels of specific proteins. The Stalix platform removes ubiquitin (destroys) labels from specific proteins to stabilize and increase the levels and activity of target proteins. Without divulging any details, Stalix will be in the fields of rare diseases, cancer and immunological disorders. The company has identified cystic fibrosis as a disease that could benefit from its approach.
Developing into the next generation of smart lab solutions, Strateos has won $ 56.1 million Series B funds to accelerate the discovery of life sciences. Strateos’ SmartLab platform integrates data generation and AI activation for a more automated R&D process. “Life sciences research needs faster, more reliable and lower cost data to take full advantage of artificial intelligence-based analysis tools,” said Mark Fischer-Colbrie, CEO of Strateos. “Our unique fleet of laboratory automation modules, accessible from anywhere in the world, accelerates the design-manufacture-test-analysis cycle and generates clean, AI-enabled data. … Strateos is reinventing the world of life science research and ushering in a new era of decentralized discovery.
COVID-19 Population Genomics and Testing Company Helix Rounded Up $ 50 million in his Series C funding to expand its genomics platform and its COVID-19 testing and viral surveillance efforts. The platform enables companies to accelerate the integration of genomic data into clinical care. “In the field of health, the objective is to obtain more personalized, preventive and population-based health care. A central part of this is identifying those at risk for genetic diseases earlier and more broadly, ”said Amr Kronfol, managing director of Warburg Pincus, a Helix investor company. Helix is also leveraging its sequencing to detect, characterize and better understand the impact of emerging strains of COVID-19.
After the raises of series A and B, entrinsic won another one $ 49 million this week in growth capital thanks to financing from Jefferies Group. According to the CEO of entrinsic, the company’s platform is “a new modality for creating highly effective, safe and cost-effective functional ingredients and active pharmaceutical ingredients (APIs).” Originally launched with a grant from NASA | BARDA, its approach uses the modulation of proteins and ion channels. The funds will be used to support ongoing marketing efforts with leading OTC, CPG and therapeutics companies.
In a round table co-led by the Korean company Mirae Asset Capital, the English biotechnology Iksuda has garnered $ 47 million develop key antibody-drug conjugate assets and expand its platform technologies. The Company’s leading preclinical ADC candidate, IKS03, targets CD19 for B-cell cancers. These new funds will propel IKS03 into the first phase I clinical trials in humans, as well as two earlier stage programs for dossiers IND. Iksuda’s programs target tumors with high relapse rates and limited treatment options.
Brain interference platform company Synchron has landed $ 40 million in a Series B round. With access to the jugular vein, Synchron is leading the way in minimally invasive implantable brain-computer interface technology. An Australian clinical trial is underway with four patients already implanted to hopefully improve their functional independence. These funds will be used to launch a pivotal study in the United States for patients with limb paralysis and to develop a pipeline of neurointerventional sensing and stimulation products.